Korean company to launch cancer diagnosis kit:
This article was originally published in Clinica
Hanmi Pharmaceuticals is preparing to launch a home blood test kit which claims to diagnose gastric, lung, colorectal and breast cancer. The four-hour long test claims "up to" 94.7% accuracy, by measuring levels of TGF-beta - a growth factor correlated with the early presence of cancers. Hanmi plans to launch the kit this year in Korea and is applying for international patents.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.